Myeloproliferative neoplasms originate from genetic mutations arising within hematopoietic stem cells, the progenitors of blood cell lineages. Over time, these mutated stem cells can lead to progressive bone marrow fibrosis, or scarring, impairing the marrow’s ability to produce healthy blood. This pathological scarring culminates in myelofibrosis, a debilitating condition characterized by anemia and bone marrow failure. Moreover, a significant subset of patients experience disease evolution to an accelerated phase resembling acute leukemia, marked by high mortality rates and limited therapeutic options. Currently, there are no universally curative treatments available for most MPN patients.

Chimeric antigen receptor (CAR) T cell therapy represents a transformative advance in hematologic oncology, enabling the reprogramming of patient-derived cytotoxic T lymphocytes to identify and attack malignant cells with extraordinary specificity. While CAR T cells have revolutionized treatment for certain leukemias and lymphomas, their application to MPNs has faced challenges due to the difficulty of isolating unique markers on malignant stem cells without affecting normal hematopoiesis. This new study, published in Science Translational Medicine, reports the successful design of CAR T cells that target the aberrant CALR protein expressed on the surface of mutant stem cells, thus providing an exploitable vulnerability.

The research team employed a comprehensive suite of experimental models, including patient-derived samples, sophisticated three-dimensional organoids mimicking human bone marrow architecture, and in vivo murine models, to validate the efficacy and selectivity of the CALR-targeted CAR T cells. These CAR T cells demonstrated potent cytotoxicity against CALR-mutant cells, effectively depleting disease-driving populations while leaving non-mutant blood cells unharmed. This selective depletion is crucial to preserving normal hematopoiesis and minimizing adverse effects.

Significantly, the three-dimensional bone marrow organoid model employed in the study recapitulated the fibrotic and complex microenvironment of myelofibrosis. The ability of CAR T cells to infiltrate this dense, scarred environment and execute targeted killing provides encouraging evidence for their potential clinical effectiveness in the hostile tumor milieu typically resistant to therapy. Organotypic models like these bridge the gap between in vitro studies and human clinical trials by faithfully replicating disease conditions, offering invaluable insights into real-world therapeutic dynamics.

Further insights emerged concerning the efficacy of CAR T cell therapy in the more aggressive, accelerated phase of MPN, where target protein expression diminishes. The team found that treatment with eltrombopag, a thrombopoietin receptor agonist used clinically to elevate platelet counts, enhanced CALR display on mutant cells. This upregulation significantly improved CAR T cell recognition and killing efficiency, suggesting an adjunctive therapeutic strategy to overcome immune evasion in advanced disease stages.

In vivo experiments using xenotransplant mouse models of myelofibrosis revealed that CALR-specific CAR T cells not only controlled leukemic proliferation but also conferred a meaningful survival advantage. These data strongly support the translational potential of this therapy and underpin plans for a Phase I clinical trial at University College London Hospital (UCLH), anticipated to commence within one to two years, pending regulatory approvals and funding acquisition.

Standard treatment paradigms for MPNs currently involve JAK inhibitors, which ameliorate symptoms by modulating cytokine signaling pathways but fail to eradicate the underlying malignant stem cells. Consequently, most patients eventually develop resistance and disease progression ensues. Allogeneic bone marrow transplantation remains the sole potentially curative option, albeit limited by donor availability, patient fitness, and a high mortality risk from transplantation complications. The advent of CAR T cell therapy tailored to CALR mutations may revolutionize this therapeutic landscape by offering a targeted, less toxic alternative.

Dr. Alex Rampotas, the study’s lead author, highlighted the therapeutic promise of this strategy, emphasizing its precision and potential to induce durable remissions. By exploiting the CALR mutation as a neoantigenic “flag,” the CAR T cells can discriminate malignant clones from normal counterparts, “turbo-boosting” the immune response to root out the disease at its source. This selective eradication stands to restore normal blood cell production, shifting treatment goals from symptomatic relief to genuine disease modification.

Professor Beth Psaila, a senior author from Oxford, underscored the importance of the advanced organoid models in elucidating the complex interactions within fibrotic bone marrow and facilitating the evaluation of novel immunotherapies. These models enable single-cell resolution analyses in human tissue contexts, accelerating the refinement of CAR T cell therapies and potentially guiding personalized treatment approaches in myelofibrosis and related blood cancers.

MPNs are categorized as rare diseases, yet their cumulative incidence in the UK approaches 4,000 new diagnoses annually, equating to about eight cases per 100,000 population. Among these, CALR-mutated MPNs comprise approximately one-third, translating to hundreds of new patients yearly who could benefit from such specialized therapies. Given the chronic nature of MPNs, this strategy also holds promise to transform long-term disease management for the substantial patient population living with these cancers.

The research consortium is actively engaged in securing resources and navigating regulatory pathways to initiate clinical testing of the CALR-targeted CAR T cells. Should early-phase trials demonstrate safety and efficacy, broader clinical deployment and patient access could feasibly occur within the early to mid-2030s. This timeline reflects realistic developmental trajectories for sophisticated cellular therapeutics but underscores the urgency for continued support in this promising frontier.

This study exemplifies the forefront of personalized cancer immunotherapy, where genetic mutations define bespoke immune interventions capable of surgically excising malignant stem cells. By coupling molecular insights with innovative cell engineering and physiologically relevant models, the research charts a course toward transformative treatments with the potential to rewrite prognoses for patients grappling with myeloproliferative neoplasms.

Subject of Research: Cells
Article Title: CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
News Publication Date: 1-Jul-2026
Web References: www.science.org/doi/10.1126/scitranslmed.adz3553
References: DOI 10.1126/scitranslmed.adz3553, Science Translational Medicine
Keywords: CAR T cell therapy, myeloproliferative neoplasms, myelofibrosis, calreticulin mutation, hematopoietic stem cells, immunotherapy, bone marrow organoids, leukemia, eltrombopag, blood cancer, targeted therapy

Myeloproliferative neoplasms are a group of disorders characterized by the excessive production of blood cells due to clonal proliferation of hematopoietic stem cells. At the heart of their pathogenesis lies hyperactivation of the JAK-STAT pathway, a critical signaling node regulating cell proliferation and survival. Mutations in JAK2, particularly the V617F point mutation, are among the most common drivers of these diseases, making JAK kinases an obvious target for drug development. JAK inhibitors such as ruxolitinib have transformed clinical management, offering symptom relief and survival benefits. Yet, the precise biological mechanisms by which they exert these effects remained incompletely understood.

The research team employed sophisticated genetically engineered mouse models that faithfully recapitulate human MPN pathology. Through a series of elaborate in vivo and ex vivo experiments, they probed the cellular and molecular consequences of JAK1/2 inhibition, evaluating not only tumor cell signaling but also broader physiological impacts. Contrary to expectations, the data demonstrated that JAK1/2 inhibitors did not primarily mediate their efficacy through direct attenuation of oncogenic signaling pathways within the malignant clones themselves. This surprising finding challenges the dogma that the therapeutic benefits observed arise from simple suppression of mutated JAK activity in cancer cells.

Detailed phosphoproteomic analyses revealed that JAK1/2 inhibition failed to significantly reduce aberrant STAT phosphorylation in neoplastic cells, indicating that canonical downstream signaling can persist despite pharmacologic blockade. Moreover, genetic ablation of JAK1/2 activity selectively in malignant cells did not fully replicate the therapeutic outcomes seen with systemic drug treatment. These insights suggest that alternative mechanisms—possibly involving the tumor microenvironment or systemic immune modulation—play pivotal roles in mediating drug response.

Further investigations highlighted the complexity of cellular crosstalk in MPNs, revealing that JAK inhibition reshapes cytokine networks, inflammatory milieu, and stromal cell interactions. The researchers observed marked alterations in the bone marrow niche and immune cell subsets following treatment, pointing toward a model where JAK1/2 inhibitors recalibrate the non-malignant components of the hematopoietic ecosystem to restore homeostasis. This nuanced understanding paves the way for combination strategies that leverage these indirect pathways to maximize therapeutic impact.

Importantly, the study sheds light on potential resistance mechanisms and clinical variability in patient responses. Since malignant signaling persists despite JAK1/2 blockade, residual neoplastic cells may survive and contribute to disease progression or relapse. This emphasizes the need for novel agents that target complementary pathways or enhance immune-mediated clearance for durable remissions. Moreover, biomarkers distinguishing patients who depend more heavily on oncogenic signaling versus microenvironmental factors could guide personalized treatment approaches.

The methodological rigor of this investigation sets a new standard in cancer modeling. By integrating genetic tools with pharmacological interventions and multi-omics profiling, the researchers have constructed a comprehensive portrait of MPN biology under therapeutic pressure. Such holistic frameworks are crucial in dissecting the complexities of cancer pathophysiology, where single-target paradigms often fall short. The findings highlight the power of preclinical models to reveal unexpected biology that can inform clinical innovation.

This paradigm shift also prompts reevaluation of JAK inhibitor use in other malignancies and inflammatory diseases where these kinases play roles. Understanding that efficacy might arise from systemic immunomodulation rather than direct tumor suppression could influence dosing regimens, timing, and combination with immunotherapies. It underscores the importance of monitoring not only malignant cells but also the host environment during treatment, which may hold keys to optimizing outcomes.

The study’s implications extend beyond therapeutic strategy, touching on fundamental cancer biology concepts. The decoupling of oncogenic signaling inhibition from clinical benefit illustrates the adaptability of cancer ecosystems and the multifaceted nature of drug actions. It invites deeper exploration into how cancer cells co-opt or evade microenvironmental control and how therapies can disrupt these malignant alliances. Future research spurred by these insights will likely explore novel targets and pathways that complement JAK1/2 inhibition.

Clinicians will also find these findings valuable in interpreting patient responses and side effect profiles. The immunological effects of JAK inhibitors, often associated with increased infection risk, must be balanced against their anti-neoplastic benefits mediated via host modulation. Personalized monitoring of immune parameters and bone marrow architecture could become integral to managing patients on these therapies.

In addition, pharmaceutical development pipelines stand to benefit greatly from these revelations. Drug discovery efforts may pivot to compounds that synergize with JAK inhibitors by reinforcing microenvironmental normalization, dampening pro-tumor inflammation, or enhancing anti-tumor immunity. The current study offers a roadmap for rational combination regimens and biomarker-driven trials, accelerating translation into the clinic.

Overall, the work by Gorantla and colleagues constitutes a milestone in MPN research, challenging established paradigms and illuminating new avenues for improving patient care. By demonstrating that the efficacy of JAK1/2 inhibitors in murine models is not directly mediated by targeting oncogenic signaling, this study refocuses attention on the broader biological context of cancer therapy. It is a compelling example of how nuanced mechanistic insights can reshape treatment landscapes and inspire innovative approaches against stubborn malignancies.

As further studies build upon these findings, we may witness the emergence of next-generation treatments exploiting non-cancer cell populations or immune regulatory circuits. Such multi-dimensional strategies promise to transcend the limits of single-target interventions and deliver more durable, effective therapies for patients afflicted with myeloproliferative neoplasms and beyond. This research underscores the evolving complexity and promise of cancer precision medicine in the 21st century.

Subject of Research:
Investigation of the mechanisms underlying the therapeutic efficacy of JAK1/2 inhibition in murine models of myeloproliferative neoplasms, focusing on the role of oncogenic signaling versus systemic and microenvironmental effects.

Article Title:
Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling.

Article References:
Gorantla, S.P., Rassner, M., Crossley, K.A. et al. Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling. Nat Commun 16, 4833 (2025). https://doi.org/10.1038/s41467-025-60019-6

Image Credits: AI Generated